Analysts bearish on Surgery Partners — 4 insights

After Zacks Investment Research downgraded Surgery Partners from a hold to a sell, other analysts are following suit, Transcript Daily reports.

Advertisement

Here’s what you should know:

1. BidaskClub assigned Surgery Partners a sell rating in its latest research note.

2. Stifel Nicolaus assigned the company a hold rating, but dropped its price objective from $19 a share to $18 a share.

3. On average analysts project a price target of $21.40 for Surgery Partners.

4. Surgery Partners closed Jan. 24 at $21.38.

More articles on transactions/valuations:
Concord Orthopaedics’ ASC plans up in the air due to rezoning concerns: 4 takeaways
Compass Surgical Partners opens multispecialty ASC & more — 5 ASC company key notes
Compass Surgical Partners opens freestanding Florida ASC: 4 key points

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Is ambulatory care healthcare’s big margin engine? 4 leaders weigh in

Wednesday, July 29
1:00 PM - 2:00 PM CDT

Presenters: Joe Ganley, athenahealthJeffrey Flynn, CASC, Gramercy Surgery CenterBryan Tsao, Access Center, Loma Linda University HealthJason Zepeda, Northridge Hospital Medical Center, CommonSpirit HealthGreg DeConciliis, PA-C, CASC, Boston Out­Patient Surgical Suites

Advertisement

Next Up in ASC Transactions & Valuation Issues

Advertisement

Comments are closed.